RecruitingNot ApplicableNCT05876130

Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer

Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer: A Prospective Phase II Trial (POHIM_EM Trial)


Sponsor

Samsung Medical Center

Enrollment

92 participants

Start Date

Nov 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study looks at a type of radiation therapy called hypofractionated IMRT — which delivers radiation in fewer, larger doses — for women with stage III endometrial (uterine) cancer who have already had surgery. The goal is to find out whether this approach is as safe and effective as standard radiation. **You may be eligible if...** - You have been confirmed with endometrioid-type endometrial cancer - You have had a hysterectomy and full surgical staging - Your cancer is at FIGO Stage III - You have had or are planning chemotherapy - You are in good physical health (ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have had previous radiation to the pelvis - You have another serious or unstable medical condition - You have a history of another cancer (except thyroid cancer, skin cancer, or endometrial cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONPOHIM_EM

hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)


Locations(1)

Samsung Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05876130


Related Trials